Fasting Blood Glucose with Serum Creatinine Levels in Type 2 Diabetes Mellitus Patients

Yohan Trayanus Lasarus Djaha; Maria Kurni Menga; Darmi Arda

doi:10.61099/jih.v2i2.259

Authors

Yohan Trayanus Lasarus Djaha Department of Nursing, Politeknik Sandi Karsa, South Sulawesi, Indonesia https://orcid.org/0009-0004-8878-2293
Maria Kurni Menga Department of Nursing, Politeknik Sandi Karsa, South Sulawesi, Indonesia https://orcid.org/0000-0001-5679-3001
Darmi Arda Department of Nursing, Politeknik Sandi Karsa, South Sulawesi, Indonesia https://orcid.org/0000-0001-8153-153X

DOI:

https://doi.org/10.61099/jih.v2i2.259

Keywords:

fasting blood glucose, serum creatinine, type 2 diabetes mellitus, renal function, diabetic nephropathy

Abstract

Introduction: Type 2 Diabetes Mellitus (T2DM) is a major global health problem associated with various chronic complications, particularly diabetic nephropathy. Persistent hyperglycemia can damage renal microvasculature and lead to impaired kidney function. Fasting blood glucose (FBG) is commonly used to assess glycemic control, while serum creatinine is a key indicator of renal function. Understanding the relationship between these parameters is important for early detection of kidney complications among patients with T2DM. This study aimed to analyze the relationship between fasting blood glucose levels and serum creatinine levels in patients with Type 2 Diabetes Mellitus in a primary healthcare setting.

Research Methodology: This study employed an analytical observational design using a cross-sectional approach. Data were collected from medical records of patients with Type 2 Diabetes Mellitus at UPT Puskesmas Buki, Indonesia, in March 2026. A total of 38 patients who met the inclusion criteria were selected using purposive sampling. Fasting blood glucose levels were measured using the enzymatic GOD-PAP method, while serum creatinine levels were determined using the Jaffe reaction method. Data were analyzed using descriptive statistics and Spearman’s rank correlation test with a significance level of p ≤ 0.05.

Results: The mean fasting blood glucose level was 176.4 ± 42.5 mg/dL, while the mean serum creatinine level was 1.18 ± 0.36 mg/dL. Statistical analysis revealed a moderate positive correlation between fasting blood glucose and serum creatinine levels (r = 0.421; p = 0.009). This indicates that higher fasting blood glucose levels tend to be associated with increased serum creatinine levels.

Conclusions: Fasting blood glucose levels are significantly associated with serum creatinine levels among patients with Type 2 Diabetes Mellitus. Regular monitoring of glycemic status and renal function in primary healthcare settings is essential for early detection and prevention of diabetic kidney complications.

Downloads

Download data is not yet available.

References

[1] T. A. Adetunji et al., “Ramadan fasting intentions and IDF-DAR risk stratification among Nigerian patients with diabetes mellitus: A multicentre, cross-sectional study,” Endocr. Metab. Sci., p. 100299, 2026, doi: https://doi.org/10.1016/j.endmts.2026.100299.

[2] E. H. Alfalogy, R. T. Almatrafi, K. M. Alshahrani, and N. H. Hariri, “Prevalence and Determinants of Suboptimal Glycemic Control in Type 2 Diabetes Mellitus Patients in Primary Health Care,” Open Public Health J., vol. 18, 2025, doi: https://doi.org/10.2174/0118749445374735250313045909.

[3] R. S. Al-Salman, M. M. Al-Ahmad, and H. Alameri, “Trends in Total Antioxidant Status and Other Biochemical Parameters in Type 2 Diabetes Mellitus: A Case-control Study,” Curr. Diabetes Rev., vol. 22, no. 2, 2026, doi: https://doi.org/10.2174/0115733998336940241219182916.

[4] Y. Fang et al., “Relationship between flow-mediated dilation and urinary albumin-creatinine ratio in patients with type 2 diabetes mellitus,” J. Diabetes Complications, vol. 39, no. 10, p. 109162, 2025, doi: https://doi.org/10.1016/j.jdiacomp.2025.109162.

[5] J.-X. Gu et al., “Correlation of glycosylated apolipoprotein A1 and glycosylated low-density lipoprotein cholesterol levels with glucose homeostasis and the risk of developing type 2 diabetes mellitus,” Diabetes Res. Clin. Pract., vol. 223, p. 112155, 2025, doi: https://doi.org/10.1016/j.diabres.2025.112155.

[6] R. Gwini, E. Sibanda, D. Mwembe, F. J. Pirie, and A. A. Motala, “Etiologic Types and Complications of Diabetes Mellitus in Newly Diagnosed Patients at Health Institutions in Bulawayo, Zimbabwe: Protocol for a Cross-Sectional and Prospective Observational Study,” JMIR Res. Protoc., vol. 15, 2026, doi: https://doi.org/10.2196/74186.

[7] Z. A. Hashim, “Connotation of serum levels of vitamin D3 and LL-37 with urinary tract infection in type 2 diabetic patients,” Clin. Epidemiol. Glob. Heal., vol. 38, p. 102299, 2026, doi: https://doi.org/10.1016/j.cegh.2026.102299.

[8] E. Herwana, Yenny, Alvina, Kurniasari, C. A. Febinia, and Pusparini, “Sirtuin, irisin, and vitamin D as predictors of diabetes mellitus with uncontrolled glycemia in Indonesian patients,” Endocr. Metab. Sci., vol. 17, p. 100214, 2025, doi: https://doi.org/10.1016/j.endmts.2024.100214.

[9] A. Hliel, H. Ahmed, and H. Hasan, “Assessment and prediction of diabetic kidney disease in patients with type 2 diabetes mellitus by using an advanced biomarkers,” Nefrología, vol. 45, no. 6, p. 101330, 2025, doi: https://doi.org/10.1016/j.nefro.2025.03.001.

[10] A. Hliel, H. Ahmed, and H. Hasan, “Assessment and prediction of diabetic kidney disease in patients with type 2 diabetes mellitus by using an advanced biomarkers,” Nefrol. (English Ed., vol. 45, no. 6, p. 101330, 2025, doi: https://doi.org/10.1016/j.nefroe.2025.101330.

[11] Y. Jiang et al., “The correlation between patients with type 2 diabetes mellitus and chronic microvascular complications during the glucose peak time,” J. Diabetes Complications, vol. 38, no. 11, p. 108866, 2024, doi: https://doi.org/10.1016/j.jdiacomp.2024.108866.

[12] K. A. K. Khan, M. Khalid, S. T. Parapur, M. Doni, and N. Husain, “Comparative efficacy of Sat-i Gilo and metformin hydrochloride in the management of Type 2 diabetes mellitus: a randomized controlled trial,” Phytomedicine Plus, vol. 5, no. 3, p. 100847, 2025, doi: https://doi.org/10.1016/j.phyplu.2025.100847.

[13] K. Konur, H. B. Polat, E. Karavar, and T. Ayaz, “Magnesium Level and Related Factors in Type 2 Diabetes Mellitus: A Cross-Sectional Study,” Endocr. Metab. Immune Disord. - Drug Targets, vol. 26, 2026, doi: https://doi.org/10.2174/0118715303411661250721141050.

[14] Y. Le et al., “Baseline metabolite profiles predict the glucose-lowering efficacy of exenatide in patients with type 2 diabetes,” Metab. Open, vol. 29, p. 100453, 2026, doi: https://doi.org/10.1016/j.metop.2026.100453.

[15] C. Liu, S. Chao, L. Jia, Q. Yang, Q. Chen, and Y. Niu, “Integrative analyses of 16S rDNA sequencing and serum metabolomics demonstrate significant roles for the oral microbiota and serum metabolites in post-kidney transplant diabetes mellitus,” Microbiol. Spectr., vol. 13, no. 7, 2025, doi: https://doi.org/10.1128/spectrum.00892-25.

[16] I. Mrosewski et al., “Menaquinone-7 and its therapeutic potential in type 2 diabetes mellitus based on a Zucker diabetic fatty rat model,” Heliyon, vol. 10, no. 23, p. e40826, 2024, doi: https://doi.org/10.1016/j.heliyon.2024.e40826.

[17] M. Pathak et al., “Effect of sodium-glucose Co-transporter 2 inhibitors on MCP-1 and uromodulin levels in patients with type 2 diabetes mellitus,” Clin. Epidemiol. Glob. Heal., vol. 31, p. 101888, 2025, doi: https://doi.org/10.1016/j.cegh.2024.101888.

[18] L. Petrova, K. Andreevska, and V. Petkova, “Efficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes mellitus: a systematic review,” PHARMACIA, vol. 73, pp. 1–28, 2026, doi: https://doi.org/10.3897/pharmacia.73.e184419.

[19] A. Slon and M. Mazaki-Tovi, “Alterations in serum concentrations of visfatin and betatrophin in dogs with diabetes mellitus,” Domest. Anim. Endocrinol., vol. 91, p. 106914, 2025, doi: https://doi.org/10.1016/j.domaniend.2025.106914.

[20] S. Suprapto, K. Bte Muhammad, and R. Rahman, “Integrated Education to Improve Treatment Adherence for Type 2 Diabetes Mellitus Patients in Makassar,” J. Pengabdi. Masy. Edukasi Indones., vol. 3, no. 1, pp. 38–46, Jan. 2026, doi: https://doi.org/10.61099/jpmei.v3i1.172.

[21] C. Traechslin et al., “Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus,” J. Clin. Transl. Endocrinol., vol. 40, p. 100393, 2025, doi: https://doi.org/10.1016/j.jcte.2025.100393.

[22] Z. Ula, R. Rahagia, and Suprapto, “Analysis of Factors Affecting Healthy Reproductive Behavior in Adolescents in the Digital Era,” J. Heal. Sci. Med. Dev., vol. 4, no. 3, pp. 127–143, 2025.

[23] J. Wei et al., “Polycyclic aromatic hydrocarbons weaken the protective effects of serum fatty acids on fasting blood glucose,” Ecotoxicol. Environ. Saf., vol. 303, p. 118869, 2025, doi: https://doi.org/10.1016/j.ecoenv.2025.118869.

[24] J. Yang, J. Chen, and L. Shen, “Construction of a nomogram prediction model for screening of serum markers for lower extremity vasculopathy secondary to type 2 diabetes mellitus,” SLAS Technol., vol. 35, p. 100352, 2025, doi: https://doi.org/10.1016/j.slast.2025.100352.

[25] M. Yaseri, H. S. Fayazi, F. Mahdi, F. Motevali, and S. S. Mortazavi Khatibani, “The status of thyroid disorders among patients with type 2 diabetes mellitus in Guilan province, Iran,” Endocr. Metab. Sci., vol. 19, p. 100267, 2025, doi: https://doi.org/10.1016/j.endmts.2025.100267.

[26] B. Zhao, M. Zhang, Z. Zhang, Y. Liang, and Z. Yang, “Association of increased serum I-309 with renal function impairment and diabetic kidney disease in type 2 diabetes mellitus,” Endocr. Connect., vol. 14, no. 8, 2025, doi: https://doi.org/10.1530/EC-25-0252.

[27] X. M. Zhen, A. R. Purcell, S. J. Glastras, S. Twigg, and J. Wong, “The effects of low carbohydrate diets including intermittent fasting on body weight, glycaemia, and quality of life measures in adults with type 1 diabetes and overweight/obesity: a systematic review,” Nutr. Metab. Cardiovasc. Dis., p. 104641, 2026, doi: https://doi.org/10.1016/j.numecd.2026.104641.

[28] Z. Zulfiah, Y. Kadang, and S. Suprapto, “Correlation Between Knowledge and Attitude Toward Treatment Adherence Among Patients with Type 2 Diabetes Mellitus in Makassar, Indonesia,” Media Kesehat. Politek. Kesehat. Makassar, vol. 20, no. 2, pp. 304–309, Dec. 2025, doi: https://dx.doi.org/10.32382/medkes.v20i2.1709.